• PDF / 169,602 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 35 Downloads / 154 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: case report A 46-year-old man developed epistaxis during treatment with bevacizumab. Additionally, he developed fatigue, thrombocytopenia, elevated serum AST and ALT while receiving bevacizumab and sintilimab for HBV-associated hepatocellular carcinoma (HCC) with multiple lung metastasis. The man with chronic hepatitis B virus (HBV)-associated liver cirrhosis presented with continuously elevated alpha-fetoprotein (AFP) and recurrent tumors. Four years ago, he was diagnosed with HCC, Barcelona Clinic Liver Cancer (BCLC) stage A. On current presentation, a clinical diagnosis of BCLC stage C was made after investigation. Subsequently, he started receiving combination therapy containing sintilimab and bevacizumab [IBI305] in June 2019 for HBV-associated HCC with multiple lung metastasis. Sintilimab was administered at a dose of 200mg over a period of 30–60 minutes [route not stated] and IV bevacizumab at a dose of 15 mg/kg body weight at every 3 weeks cycle. During treatment, he developed adverse event (AE) stage I epistaxis attributed to bevacizumab. Additionally, he developed stage I fatigue, thrombocytopenia, elevated serum AST and stage II elevated serum ALT, attributed to both bevacizumab and sintilimab [durations of treatments to reactions onsets and outcomes not stated]. Duan X, et al. Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis. 803500003 Digestive and Liver Disease 52: 794-796, No. 7, Jul 2020. Available from: URL: http://doi.org/10.1016/j.dld.2020.04.005

0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Sep 2020 No. 1820